Survodutide: difference between revisions
Diff·revision 11 → 12·23:26, 25 Apr 2025
Difference between revision 11 and revision 12 of Survodutide. 1 line changed; the page grew by 40 bytes.
| Revision 11 — 21:20, 8 Apr 2025 SemaglutideSasha (talk) add the year of first marketing authorisation, with the regulator named 4,470 bytes ±0 | Revision 12 — 23:26, 25 Apr 2025 TSH_Tallulah (talk) convert the substitution list to a table so the analogues line up 4,510 bytes +40 | ||
|---|---|---|---|
| 7 | | Status = Phase 3; not approved | 7 | | Status = Phase 3; not approved |
| 8 | }} | 8 | }} |
| + | 9 | {{medical|talk=Investigational status}} | |
| 9 | 10 | ||
| 10 | '''Survodutide''' (development code '''BI 456906''') is an investigational peptide that agonises both the [[Glucagon|glucagon]] receptor and the [[GLP-1 receptor]]. It is under phase 3 evaluation for obesity and has been studied in metabolic dysfunction-associated steatohepatitis. It is not approved for use in any indication.{{r|zimmermann2022}} | 11 | '''Survodutide''' (development code '''BI 456906''') is an investigational peptide that agonises both the [[Glucagon|glucagon]] receptor and the [[GLP-1 receptor]]. It is under phase 3 evaluation for obesity and has been studied in metabolic dysfunction-associated steatohepatitis. It is not approved for use in any indication.{{r|zimmermann2022}} |